Why is Switzerland's pharmaceutical industry at risk of a US Section 301 trade investigation, according to Interpharma?

Switzerland is at risk because it is currently reviewing measures to reduce mandatory healthcare prices—including lowering drug prices—which the industry has criticized, and Interpharma’s CEO René Buholzer stated it is 'clear that Switzerland is also a potential target in light of the current (health insurance ordinance) revision'; this follows a similar US Section 301 investigation launched against Germany after Berlin proposed overhauling its statutory healthcare system to cut pharmaceutical spending, and aligns with a recent letter from Republican US congressmen urging the U.S. Trade Representative and Commerce Secretary to investigate both Germany and Switzerland for 'unfair foreign pharmaceutical pricing policies' that 'free-ride off the United States' by shifting the burden of pharmaceutical innovation onto US consumers.

What specific policy change in Switzerland has raised concerns about triggering US trade action?

The specific policy change is Switzerland’s ongoing revision of its health insurance ordinance, which includes measures aimed at reducing mandatory healthcare prices—particularly drug prices—a development that Interpharma’s CEO René Buholzer explicitly linked to the risk of a US Section 301 investigation, noting that 'it is clear that Switzerland is also a potential target in light of the current (health insurance ordinance) revision', and that the industry has criticized these planned price-lowering measures.

Swiss pharma at risk of US trade investigation, industry body says

Jun 26, 2026

The U.S. may launch a Section 301 trade investigation into Switzerland's pharmaceutical sector over potential price cuts, mirroring actions against Germany. Industry leaders warn this could impact major exporters like Roche and Novartis amidst rising tensions over drug pricing policies.

reuters

2026-06-07

Swiss Firms Invest $27 Billion in US After Tariff Deal, NZZ am Sonntag Reports

2026-06-26

Swiss pharma at risk of US trade investigation, industry body says

2026-08-14

Swiss Economy Surges Far More Than Forecast, Led by Pharma

Swiss pharma at risk of US trade investigation, industry body says

FAQ